McDermott+ is pleased to bring you Regs & Eggs, a weekly Regulatory Affairs blog by Jeffrey Davis. Click here to subscribe to future blog posts. July 2, 2025 – There has been a lot of talk recently ...
Darzalex Faspro significantly reduced disease progression risk in high-risk smoldering multiple myeloma, with a 51% reduction compared to active monitoring. The AQUILA study showed a median ...
Patient-reported physical function scores are significant predictors of survival and adverse events in multiple myeloma treatment. Physical function has a stronger correlation with patient outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback